.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin led to improved progression-free as well as total survival, leading to FDA commendation as well as a brand new procedure alternative for patients.